<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34935174</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development.</ArticleTitle><Pagination><StartPage>165</StartPage><EndPage>175</EndPage><MedlinePgn>165-175</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.26285</ELocationID><Abstract><AbstractText>Current therapeutic development in amyotrophic lateral sclerosis (ALS) relies on individual randomized clinical trials to test a specific investigational product in a single patient population. This approach has intrinsic limitations, including cost, time, and lack of flexibility. Adaptive platform trials represent a novel approach to investigate several interventions for a single disease in a continuous manner. Already in use in oncology, this approach is now being employed more often in neurology. Here, we describe a newly launched platform trial for ALS. The Healey ALS Platform Trial is testing multiple investigational products concurrently in people with ALS, with the goal of rapidly identifying novel treatments, biomarkers, and trial endpoints. ANN NEUROL 2022;91:165-175.</AbstractText><CopyrightInformation>&#xa9; 2021 American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0505-1168</Identifier><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS and Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS and Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Quintana</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Berry Consultants, Austin, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macklin</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saville</LastName><ForeName>Benjamin R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Berry Consultants, Austin, TX.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Detry</LastName><ForeName>Michelle A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Berry Consultants, Austin, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chase</LastName><ForeName>Marianne</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS and Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherman</LastName><ForeName>Alexander V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS and Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS and Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drake</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS and Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Jinsy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Columbia University, New York City, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Barrow Neurological Institute, Phoenix, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chibnik</LastName><ForeName>Lori B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vestrucci</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Berry Consultants, Austin, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS and Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Healey ALS Platform Trial Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>ALS Finding A Cure</Agency><Country/></Grant><Grant><Agency>ALS One</Agency><Country/></Grant><Grant><Agency>AMG Charitable Foundation</Agency><Country/></Grant><Grant><Agency>Arthur M. Blank Family Foundation</Agency><Country/></Grant><Grant><Agency>I AM ALS</Agency><Country/></Grant><Grant><Agency>Muscular Dystrophy Association</Agency><Country/></Grant><Grant><Agency>Tackle ALS</Agency><Country/></Grant><Grant><Agency>Tambourine ALS Collaborative</Agency><Country/></Grant><Grant><Agency>The ALS Association</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="Y">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023381" MajorTopicYN="N">Endpoint Determination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Macklin</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quintana</LastName><ForeName>Melanie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saville</LastName><ForeName>Ben</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Detry</LastName><ForeName>Michelle A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chibnik</LastName><ForeName>Lori</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bind</LastName><ForeName>Marie Abele</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vestrucci</LastName><ForeName>Matteo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Locatelli</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alameda</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCaffrey</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berry</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Babu</LastName><ForeName>Suma</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scalia</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simmons</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grogan</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Su</LastName><ForeName>Xiaowei</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mamarabadi</LastName><ForeName>Mansoureh</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heitzman</LastName><ForeName>Daragh</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nasri</LastName><ForeName>Mohamad Asaad</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katz</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Liberty</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felice</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whitaker</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ajroud-Driss</LastName><ForeName>Senda</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quick</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kolb</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarah Heintzman</LastName><ForeName>N P</ForeName><Initials>NP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Appel</LastName><ForeName>Stanley H</ForeName><Initials>SH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson Greene</LastName><ForeName>Ericka</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thonhoff</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shroff</LastName><ForeName>Sheetal</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liao</LastName><ForeName>Bing</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Eva L</ForeName><Initials>EL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amber Malcolm</LastName><ForeName>N P</ForeName><Initials>NP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newman</LastName><ForeName>Daniel S</ForeName><Initials>DS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arcila-Londono</LastName><ForeName>Ximena</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steijlen</LastName><ForeName>Kara</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Owegi</LastName><ForeName>Margaret Ayo</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Ghasemi</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Joseph Americo M</ForeName><Initials>JAM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piccione</LastName><ForeName>Ezequiel</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thaisetthawatkul</LastName><ForeName>Pariwat</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiss</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rad</LastName><ForeName>Nassim</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ilieva</LastName><ForeName>Hristelina</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasinelli</LastName><ForeName>Piera</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Judith Guarnieri</LastName><ForeName>N P</ForeName><Initials>NP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ladha</LastName><ForeName>Shafeeq</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobsen</LastName><ForeName>Bill</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowser</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jackson</LastName><ForeName>Carlayne</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenfeld</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhuvaneswaran</LastName><ForeName>Karthikeyan</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elman</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrews</LastName><ForeName>Jinsy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Julia Yasek</LastName><ForeName>N P</ForeName><Initials>NP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fee</LastName><ForeName>Dominic</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heiman-Patterson</LastName><ForeName>Terry</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deboo</LastName><ForeName>Anahita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swenson</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nance</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vu</LastName><ForeName>Tuan</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suresh</LastName><ForeName>Niraja</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farias</LastName><ForeName>Jerrica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caress</LastName><ForeName>Jim</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cartwright</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rezania</LastName><ForeName>Kourosh</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elliott</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rutkove</LastName><ForeName>Seward</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>McIlduff</LastName><ForeName>Courtney</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stommel</LastName><ForeName>Elijah</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fournier</LastName><ForeName>Christina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>Eufrosina</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wymer</LastName><ForeName>James P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Granit</LastName><ForeName>Volkan</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lewis</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burford</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maragakis</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clawson</LastName><ForeName>Lora</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uchil</LastName><ForeName>Alpa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riley</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mosmiller</LastName><ForeName>Betsy</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Twydell</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goyal</LastName><ForeName>Namita A</ForeName><Initials>NA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jawdat</LastName><ForeName>Omar</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jabari</LastName><ForeName>Duaa</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Statland</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kasarskis</LastName><ForeName>Edward J</ForeName><Initials>EJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russell</LastName><ForeName>James W</ForeName><Initials>JW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jin</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maiser</LastName><ForeName>Sam</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Jaimin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bjorn</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bedlack</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>I-Hweii Amy</ForeName><Initials>IA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olney</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bazan</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayat</LastName><ForeName>Ghazala</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pattee</LastName><ForeName>Gary L</ForeName><Initials>GL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donofrio</LastName><ForeName>Peter D</ForeName><Initials>PD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peltier</LastName><ForeName>Amanda C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez-Thompson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nathan</LastName></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Govindarajan</LastName><ForeName>Raghav</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>Vovanti</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertorini</LastName><ForeName>Tulio</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tourenne</LastName><ForeName>Clotilde Lagier</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vakili</LastName><ForeName>Ghazaleh Sadri</ForeName><Initials>GS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chase</LastName><ForeName>Marianne</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sherman</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dagostino</LastName><ForeName>Derek</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bocchio</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eydinov</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faulconer</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kharakozova</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korin</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Novak</LastName><ForeName>Ilya</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinani</LastName><ForeName>Ervin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tarasenko</LastName><ForeName>Natalia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vigneswaran</LastName><ForeName>Prasha</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katsovskiy</LastName><ForeName>Igor</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whitworth</LastName><ForeName>Isaac</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wahab</LastName><ForeName>Yusra</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gladden</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaughnessy</LastName><ForeName>Aileen</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tustison</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jentoft</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ostrow</LastName><ForeName>Joe</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lim</LastName><ForeName>Sangwon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Changkuon</LastName><ForeName>Genevive</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mattos</LastName><ForeName>Annette De</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patterson</LastName><ForeName>Janae</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figueroa-Szostek</LastName><ForeName>Precious</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pothier</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harkey</LastName><ForeName>Brittney</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>DiStefano</LastName><ForeName>Sofia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bailey</LastName><ForeName>Abbey</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>DiOrio</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feulner</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomes</LastName><ForeName>Jassira</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DiMarzio</LastName><ForeName>Marisa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henrique</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benson</LastName><ForeName>Molly</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grabert</LastName><ForeName>Stacey</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garozzo</LastName><ForeName>Tessa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Randall</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Connolly</LastName><ForeName>Mariah</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santiago</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lavery</LastName><ForeName>Courtney</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittle</LastName><ForeName>Gale</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Jenny</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bolger</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fetouh</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kamp</LastName><ForeName>Cornelia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Small</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bulat</LastName><ForeName>Allison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drake</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGarry</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torti</LastName><ForeName>Margherita</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>22</Day><Hour>7</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34935174</ArticleId><ArticleId IdType="doi">10.1002/ana.26285</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012;2012:CD001447.</Citation></Reference><Reference><Citation>Takei K, Watanabe K, Yuki S, et al. Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:5-10.</Citation></Reference><Reference><Citation>Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004;63:1364-1370.</Citation></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 2019;39:733-748.</Citation></Reference><Reference><Citation>Adaptive Platform Trials Coalition. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat Rev Drug Discov 2019;18:797-807.</Citation></Reference><Reference><Citation>Saville BR, Berry SM. Efficiencies of platform clinical trials: a vision of the future. Clin Trials 2016;13:358-366.</Citation></Reference><Reference><Citation>Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 2017;377:62-70.</Citation></Reference><Reference><Citation>Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 2015;313:1619-1620.</Citation></Reference><Reference><Citation>Alexander BM, Ba S, Berger MS, et al. Adaptive global innovative learning environment for glioblastoma: GBM AGILE. Clin Cancer Res 2018;24:737-743.</Citation></Reference><Reference><Citation>Alexander BM, Trippa L, Gaffey S, et al. Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): a Bayesian adaptive platform trial to develop precision medicines for patients with glioblastoma. JCO Precis Oncol 2019;3:PO.18.00071.</Citation></Reference><Reference><Citation>Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100.</Citation></Reference><Reference><Citation>Bartsch R, de Azambuja E. I-SPY 2: optimising cancer drug development in the 21st century. ESMO Open 2016;1:e000113.</Citation></Reference><Reference><Citation>Carey LA, Winer EP. I-SPY 2-toward more rapid progress in breast cancer treatment. N Engl J Med 2016;375:83-84.</Citation></Reference><Reference><Citation>Papadimitrakopoulou V, Lee JJ, Wistuba II, et al. The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2016;34:3638-3647.</Citation></Reference><Reference><Citation>Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018;392:2353-2366.</Citation></Reference><Reference><Citation>Regel I, Mayerle J, Mahajan UM. Current strategies and future perspectives for precision medicine in pancreatic cancer. Cancers (Basel) 2020;12:1024.</Citation></Reference><Reference><Citation>Simon R. Critical review of umbrella, basket, and platform designs for oncology clinical trials. Clin Pharmacol Ther 2017;102:934-941.</Citation></Reference><Reference><Citation>Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 2018;29:1235-1248.</Citation></Reference><Reference><Citation>Bateman RJ, Benzinger TL, Berry S, et al. The DIAN-TU next generation Alzheimer's prevention trial: adaptive design and disease progression model. Alzheimers Dement 2017;13:8-19.</Citation></Reference><Reference><Citation>Mills SM, Mallmann J, Santacruz AM, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris) 2013;169:737-743.</Citation></Reference><Reference><Citation>Connick P, De Angelis F, Parker RA, et al. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. BMJ Open 2018;8:e021944.</Citation></Reference><Reference><Citation>Cummings J, Aisen P, Barton R, et al. Re-engineering Alzheimer clinical trials: global Alzheimer's platform network. J Prev Alzheimers Dis 2016;3:114-120.</Citation></Reference><Reference><Citation>Moulder KL, Snider BJ, Mills SL, et al. Dominantly inherited Alzheimer network: facilitating research and clinical trials. Alzheimers Res Ther 2013;5:48.</Citation></Reference><Reference><Citation>Solomon A, Kivipelto M, Molinuevo JL, et al. European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): study protocol. BMJ Open 2019;8:e021017.</Citation></Reference><Reference><Citation>Benatar M, Boylan K, Jeromin A, et al. ALS biomarkers for therapy development: state of the field and future directions. Muscle Nerve 2016;53:169-182.</Citation></Reference><Reference><Citation>Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig (Lond) 2014;4:605-618.</Citation></Reference><Reference><Citation>van Eijk RP, Eijkemans MJ, Rizopoulos D, et al. Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clin Epidemiol 2018;10:333-341.</Citation></Reference><Reference><Citation>Healy BC, Schoenfeld D. Comparison of analysis approaches for phase III clinical trials in amyotrophic lateral sclerosis. Muscle Nerve 2012;46:506-511.</Citation></Reference><Reference><Citation>Berry JD, Miller R, Moore DH, et al. The combined assessment of function and survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Front Degener 2013;14:162-168.</Citation></Reference><Reference><Citation>Gelman A, Shalizi CR. Philosophy and the practice of Bayesian statistics. Br J Math Stat Psychol 2013;66:8-38.</Citation></Reference><Reference><Citation>Jansen JP, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008;11:956-964.</Citation></Reference><Reference><Citation>Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med 1995;14:2685-2699.</Citation></Reference><Reference><Citation>Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 2001;10:277-303.</Citation></Reference><Reference><Citation>Wang G, Berry S, Xiong C, et al. A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease. Stat Med 2018;37:3047-3055.</Citation></Reference><Reference><Citation>Quintana M, Shrader J, Slota C, et al. Bayesian model of disease progression in GNE myopathy. Stat Med 2019;38:1459-1474.</Citation></Reference><Reference><Citation>Lake SL, Quintana MA, Broglio K, et al. Bayesian adaptive design for clinical trials in Duchenne muscular dystrophy. Stat Med 2021;40:4167-4184.</Citation></Reference><Reference><Citation>Howard JF Jr, Nowak RJ, Wolfe GI, et al. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol 2020;77:582-592.</Citation></Reference><Reference><Citation>Chi&#xf2; A, Mazzini L, Mora G. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology 2020;167:107986.</Citation></Reference><Reference><Citation>Wang GY, Rayner SL, Chung R, et al. Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis. Mater Today Bio 2020;6:100055.</Citation></Reference><Reference><Citation>Ionescu A, Gradus T, Altman T, et al. Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1(G93A) model. Cell Death Dis 2019;10:210.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>